Default company panoramic image

Embera NeuroTherapeutics, Inc.

Embera is a specialty pharma company developing a novel treatment for the $1.9B smoking cessation market and cocaine dependence (no approved treatments today).

  • Stage Product In Development
  • Industry Biotechnology
  • Location Sudbury, MA, USA
  • Currency USD
  • Founded January 2007
  • Employees 1
  • Website

Company Summary

Embera is developing a patented drug combination to address 2 significant unmet medical needs smoking and cocaine dependence. Embera is advancing EMB-001 for smoking cessation ($1.9B WW market), based on positive animal study results where EMB-001 compared very favorably to Chantix®, Pfizer’s $638M smoking cessation drug. Embera is also developing the cocaine dependence indication for EMB-001 a $400M product opportunity leveraging grant funding.


  • 8886f0ef caf4 41e6 9dc2 1598e48c1e69
    President & CEO

  • F73019e1 7591 4df6 b7b2 531aaf6ddd0f
    VP Preclinical Development & Regulatory Affairs

  • Be355574 9a94 4fdb 8add b866fd72e6c6
    Director of Clinical Operations

  • 9efe61d6 53e2 4af7 9707 7cd6ac8b7679
    Chief Medical Officer

  • Default avatar
    Michael Short
    VP of Strategy and Business Development


  • Default avatar
    Gunderson Dettmer Stough, Villeneuve Franklin & Hachigian, LLP
    Default avatar
    Hummingbird & King

Previous Investors

  • Default avatar
    Joe Lovett, Louisiana Fund I
    Managing Director
    Cb348170 6ccd 48c3 bd77 b9f17540fa51
    Managing Director, Louisiana Ventures, Themelios Ventures